{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:05:41Z","timestamp":1789088741342,"version":"build-2803163510"},"reference-count":66,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[1990,9,1]],"date-time":"1990-09-01T00:00:00Z","timestamp":652147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DICP"],"published-print":{"date-parts":[[1990,9]]},"abstract":"<jats:p>Fluconazole is a fluorine-substituted, bis-triazole antifungal agent. Its mechanism of action, like that of other azoles, involves interruption of the conversion of lanosterol to ergosterol via binding to fungal cytochrome P-450 and subsequent disruption of fungal membranes. Activity against Aspergillus spp., Blastomyces dermatitidis, Candida spp., Coccidioides immitis, Cryptococcus neoformans, Histoplasma capsulatum Paracoccidioides brasiliensis has been demonstrated in several animal models. Fluconazole can be admininstered both orally and intravenously. Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 \u03bcmol\/L respectively. Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89. Serum half-life is long (22\u201332 hours) and elimination is via renal clearance of unchanged drug. Clinical trials and reports support the use of fluconazole in treatment of candidiasis, particularly oropharyngeal and esophageal infections in immunocompromised hosts. Fluconazole is also approved for initial and suppresive therapy of cryptococcal meningitis. Its role in management of systemic fungal infections will be further defined once results of other comparative trials become available. Fluconazole is well tolerated and its effects on steroidogenesis are markedly less than those of ketoconazole. Antipyrine clearance is not altered at low doses (50 mg) of fluconazole; however, drug interactions with the use of larger doses can be anticipated with agents such as cyclosporin, phenytoin, oral hypoglycemics warfarin. Rifampin appears to decrease metabolic clearance of fluconazole. Fluconazole is available as oral and parenteral formulations. Once-daily doses of 100\u2013400 mg are recommended. Dosage reduction is advised for patients with impaired renal function.<\/jats:p>","DOI":"10.1177\/106002809002400914","type":"journal-article","created":{"date-parts":[[2017,6,30]],"date-time":"2017-06-30T21:46:54Z","timestamp":1498859214000},"page":"860-867","source":"Crossref","is-referenced-by-count":74,"title":["Fluconazole: A New Triazole Antifungal Agent"],"prefix":"10.1177","volume":"24","author":[{"given":"Mary T.","family":"Pasko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Piscitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea D.","family":"Van Slooten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[1990,9,1]]},"reference":[{"key":"bibr-bibr1-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.1.1"},{"key":"bibr-bibr2-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1042\/bst0110665"},{"key":"bibr-bibr3-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/19.2.171"},{"key":"bibr-bibr4-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.2.209"},{"key":"bibr-bibr5-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.12.1867"},{"key":"bibr-bibr6-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.23.2.298-301.1986"},{"key":"bibr-bibr7-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.26.9.1874-1877.1988"},{"key":"bibr-bibr8-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1080\/02681218680000461"},{"key":"bibr-bibr9-106002809002400914","first-page":"596","volume":"28","author":"O'Day DM","year":"1987","journal-title":"Invest Ophthalmol"},{"key":"bibr-bibr10-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.3.418"},{"key":"bibr-bibr11-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.2.147"},{"key":"bibr-bibr12-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.4.660"},{"key":"bibr-bibr13-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1080\/02681218680000171"},{"key":"bibr-bibr14-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.6.1249"},{"key":"bibr-bibr15-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.6.815"},{"key":"bibr-bibr16-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.5.832"},{"key":"bibr-bibr17-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1443"},{"key":"bibr-bibr18-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/19.5.663"},{"key":"bibr-bibr19-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.12.2005"},{"key":"bibr-bibr20-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.4.524"},{"key":"bibr-bibr21-106002809002400914","unstructured":"Sugar AM, Picard M, Noble L. Comparison of SCH 39304, fluconazole and amphotericin B in treatment of murine pulmonary blastomycosis (abstract). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 825."},{"key":"bibr-bibr22-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.4.579"},{"key":"bibr-bibr23-106002809002400914","unstructured":"Defaveri J, GraybillJr, SCH 39304 in treatment of murine pulmonary aspergillosis (abstract). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 822."},{"key":"bibr-bibr24-106002809002400914","unstructured":"Clemons KV, Hanson LH, Perlman AM, Stevens DA. Efficacy of SCH 39304 in a systemic model of murine coccidioidomycosis (abstract). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 823."},{"key":"bibr-bibr25-106002809002400914","unstructured":"Defaveri J, Sun SH, Graybill JR. Treatment of murine coccidioidal meningitis (abstract). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 824."},{"key":"bibr-bibr26-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1080\/02681218680000201"},{"key":"bibr-bibr27-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.5.648"},{"key":"bibr-bibr28-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb40440.x"},{"key":"bibr-bibr29-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.3.369"},{"key":"bibr-bibr30-106002809002400914","unstructured":"Kramer W, Kim H, Symchowiczg, Pharmacokinetics of SCH 39304 in man (abstract). Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988: 165."},{"key":"bibr-bibr31-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(88)80081-0"},{"key":"bibr-bibr32-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.4.806"},{"key":"bibr-bibr33-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92572-5"},{"key":"bibr-bibr34-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1080\/02681218880000081"},{"key":"bibr-bibr35-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb03483.x"},{"key":"bibr-bibr36-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.5.665"},{"key":"bibr-bibr37-106002809002400914","unstructured":"Rubin RH, Debruin MF, Knirsch AK. Fluconazole therapy for patients with serious\n                      Candida\n                      infections who have failed standard therapies (abstract). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 71."},{"key":"bibr-bibr38-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb40453.x"},{"key":"bibr-bibr39-106002809002400914","doi-asserted-by":"publisher","DOI":"10.3109\/00365548809032437"},{"key":"bibr-bibr40-106002809002400914","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-2-170_1"},{"key":"bibr-bibr41-106002809002400914","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-3-384"},{"key":"bibr-bibr42-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.903"},{"key":"bibr-bibr43-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(88)80082-2"},{"key":"bibr-bibr44-106002809002400914","unstructured":"Larsen RA, Leal ME. Fluconazole compared to amphotericin B as treatment of cryptococcal meningitis (abstract). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 1062."},{"key":"bibr-bibr45-106002809002400914","unstructured":"Dismukes W, Cloud G, Thompson S, Fluconazole versus amphotericin B therapy of acute cryptococcal meningitis (abstract). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 1065."},{"key":"bibr-bibr46-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90481-6"},{"key":"bibr-bibr47-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198901000-00021"},{"key":"bibr-bibr48-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1007\/BF01962338"},{"key":"bibr-bibr49-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(88)90071-8"},{"key":"bibr-bibr50-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1989.tb01667.x"},{"key":"bibr-bibr51-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb40456.x"},{"key":"bibr-bibr52-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.12.1859"},{"key":"bibr-bibr53-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.297.6642.178"},{"key":"bibr-bibr54-106002809002400914","unstructured":"Feczko J, Brammer KW, Buell DN. Superiority of oral fluconazole over oral non-absorbable polyenes as fungal prophylaxis in neutropenic patients (abstract). Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989: 70."},{"key":"bibr-bibr55-106002809002400914","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-10-844_1"},{"key":"bibr-bibr56-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92676-7"},{"key":"bibr-bibr57-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92657-3"},{"key":"bibr-bibr58-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(88)90291-9"},{"key":"bibr-bibr59-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90206-7"},{"key":"bibr-bibr60-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.5.646"},{"key":"bibr-bibr61-106002809002400914","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0090-9556(25)07626-3","volume":"17","author":"Ladelfa I","year":"1989","journal-title":"Drug Metab Dispos"},{"key":"bibr-bibr62-106002809002400914","first-page":"603P","volume":"21","author":"Purba HS","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"bibr-bibr63-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92353-2"},{"key":"bibr-bibr64-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6683.1315-b"},{"key":"bibr-bibr65-106002809002400914","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90343-7"},{"key":"bibr-bibr66-106002809002400914","unstructured":"Package insert. Diflucan (fluconazole). Roerig (division of Pfizer), New York, NY, January 1990."}],"container-title":["DICP"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809002400914","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809002400914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:04:15Z","timestamp":1777374255000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/106002809002400914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,9]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1990,9]]}},"alternative-id":["10.1177\/106002809002400914"],"URL":"https:\/\/doi.org\/10.1177\/106002809002400914","relation":{},"ISSN":["1042-9611"],"issn-type":[{"value":"1042-9611","type":"print"}],"subject":[],"published":{"date-parts":[[1990,9]]}}}